secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2022-06-17T23:59:59+00:00
Accession:  0001178913-22-002398
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio President of R&D & Director resigns under separation deal with cash and option benefits
--------------------------------------------------------------------------------

- Dr. Phillip Schwartz resigns as President of R&D (effective July 21, 2022) and from Board (immediate); no disagreement.
- Cash separation payment of ~$155,900 plus ~$213,952 in accrued benefits; also fully accelerated 100,000 option shares subject to shareholder approval.
- Proposed consulting agreement for business development services with 14-day termination notice.
- Schwartz agrees to non-disparagement, mutual release, and voting/standstill restrictions until after 2023 AGM.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/0001178913-22-002398-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891322002398/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001178913-22-002398

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer